A groundbreaking machine designed to preserve donated lungs could significantly enhance transplantation rates across England and Wales, potentially saving up to 80% of currently discarded organs. As the UK grapples with one of the lowest lung transplant rates globally, this innovative system offers a glimmer of hope for patients awaiting critical surgical procedures.
A Dire Need for Increased Transplantation
According to the latest statistics from NHS Blood and Transplant, there are currently 170 individuals—including six children—on the waiting list for lung transplants in the UK. Most adults face a wait of up to two years, with a staggering 20% passing away within a year of being added to the transplant list due to the unavailability of suitable organs. Alarmingly, only 23% of all donated lungs are utilised, with many being declined not solely for quality issues, but also due to staffing constraints and theatre capacity.
The new XVIVO perfusion system, recently endorsed in draft guidance by the National Institute for Health and Care Excellence (Nice), is poised to address this critical issue. The system, which keeps organs viable outside the body, is expected to be trialled within the NHS for the next four years, allowing for a comprehensive assessment of its effectiveness and cost-efficiency.
How the XVIVO System Works
This innovative machine operates by warming donated lungs to body temperature and circulating a fluid that mimics blood plasma. Simultaneously, it ventilates the lungs to simulate normal breathing. This enables transplant teams to closely monitor lung function, treat infections, drain excess fluid, and reinflate collapsed sections. Until now, the technology has only been tested in select adult transplant centres, and its application in paediatric cases had not been widely approved.
Dr. Anastasia Chalkidou, the health technology programme director at Nice, expressed optimism regarding the system’s potential. “Every donated lung is a precious gift, and right now too many of them never reach a patient who needs them,” she stated. “This technology has the potential to change that, giving transplant teams the time and information they need to make the most of organs that would otherwise go unused.”
A Step Towards Equity in Transplantation
Chalkidou also highlighted the broader implications of this initiative, noting that it aims to ensure equitable access to lung transplants across various locations and hospital sizes. Jonathan Blades, head of policy at Asthma + Lung UK, echoed these sentiments, emphasising that lung transplant rates in the UK lag behind those in other developed nations, leading to poor respiratory health outcomes.
“There is an urgent need for renewed political and research focus to transform lung health in the UK,” Blades remarked. “This new technology marks an important step towards that ambition, potentially giving more people with serious lung conditions valuable time with their loved ones.”
The Importance of Robust Evidence
Prof. Andrew Fisher, a consultant transplant physician at Newcastle upon Tyne Hospitals NHS Foundation Trust and a member of the British Transplantation Society, stressed the necessity for comprehensive evidence to demonstrate the system’s impact on lung transplantation rates. “It’s vital that we generate robust data that show how this device influences transplant activity and supports timely access for patients yearning for a suitable organ,” he asserted.
Why it Matters
The advent of the XVIVO perfusion system represents a pivotal moment in the fight for improved lung health in the UK. With a significant number of donated lungs currently going to waste, this technology not only promises to save lives but also to provide hope to countless families. As the healthcare system strives to bridge the gap in lung transplantation rates, the successful implementation of this programme could mark a transformative shift in how we approach organ donation and transplantation in the country.
